Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO

Aspen Neuroscience Inc. completed a US initial public offering, raising approximately $140.6 million. The company's shares declined 2% following the offering. Aspen Neuroscience develops cell therapies in clinical-stage trials.

• Bloomberg — Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO

Next story